Oxidative stress induced-neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier Y Gilgun-Sherki, E Melamed, D Offen Neuropharmacology 40 (8), 959-975, 2001 | 1099 | 2001 |
VPS35 mutations in Parkinson disease C Vilariño-Güell, C Wider, OA Ross, JC Dachsel, JM Kachergus, ... The American Journal of Human Genetics 89 (1), 162-167, 2011 | 1060 | 2011 |
A double-blind, delayed-start trial of rasagiline in Parkinson's disease CW Olanow, O Rascol, R Hauser, PD Feigin, J Jankovic, A Lang, ... New England Journal of Medicine 361 (13), 1268-1278, 2009 | 1053 | 2009 |
Precursor control of neurotransmitter synthesis. RJ Wurtman, F Hefti, E Melamed Pharmacological reviews 32 (4), 315-335, 1980 | 943 | 1980 |
The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy Y Gilgun-Sherki, E Melamed, D Offen Journal of neurology 251, 261-268, 2004 | 812 | 2004 |
Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily … O Rascol, DJ Brooks, E Melamed, W Oertel, W Poewe, F Stocchi, ... The Lancet 365 (9463), 947-954, 2005 | 787 | 2005 |
Antioxidant therapy in acute central nervous system injury: current state Y Gilgun-Sherki, Z Rosenbaum, E Melamed, D Offen Pharmacological reviews 54 (2), 271-284, 2002 | 772 | 2002 |
Partial lesions of the dopaminergic nigrostriatal system in rat brain: biochemical characterization F Hefti, E Melamed, RJ Wurtman Brain research 195 (1), 123-137, 1980 | 617 | 1980 |
The natural history of multiple system atrophy: a prospective European cohort study GK Wenning, F Geser, F Krismer, K Seppi, S Duerr, S Boesch, ... The lancet neurology 12 (3), 264-274, 2013 | 558 | 2013 |
Levodopa in the treatment of Parkinson's disease: current controversies CW Olanow, Y Agid, Y Mizuno, A Albanese, U Bonucelli, P Damier, ... Movement disorders 19 (9), 997-1005, 2004 | 505 | 2004 |
Validation of the freezing of gait questionnaire in patients with Parkinson's disease N Giladi, J Tal, T Azulay, O Rascol, DJ Brooks, E Melamed, W Oertel, ... Movement disorders: official journal of the Movement Disorder Society 24 (5 …, 2009 | 460 | 2009 |
The “dying-back” phenomenon of motor neurons in ALS M Dadon-Nachum, E Melamed, D Offen Journal of molecular neuroscience 43, 470-477, 2011 | 417 | 2011 |
The mystery of motor asymmetry in Parkinson's disease R Djaldetti, I Ziv, E Melamed The Lancet Neurology 5 (9), 796-802, 2006 | 417 | 2006 |
Reduction in regional cerebral blood flow during normal aging in man. E Melamed, S Lavy, S Bentin, G Cooper, Y Rinot Stroke 11 (1), 31-35, 1980 | 397 | 1980 |
Quantitative measurement of pain sensation in patients with Parkinson disease R Djaldetti, A Shifrin, Z Rogowski, E Sprecher, E Melamed, D Yarnitsky Neurology 62 (12), 2171-2175, 2004 | 374 | 2004 |
Increased plasma endothelin-1 in acute ischemic stroke. I Ziv, G Fleminger, R Djaldetti, A Achiron, E Melamed, M Sokolovsky Stroke 23 (7), 1014-1016, 1992 | 373 | 1992 |
Safety and clinical effects of mesenchymal stem cells secreting neurotrophic factor transplantation in patients with amyotrophic lateral sclerosis: results of phase 1/2 and 2a … P Petrou, Y Gothelf, Z Argov, M Gotkine, YS Levy, I Kassis, ... JAMA neurology 73 (3), 337-344, 2016 | 322 | 2016 |
Prevention of dopamine-induced cell death by thiol antioxidants: possible implications for treatment of Parkinson's disease D Offen, I Ziv, H Sternin, E Melamed, A Hochman Experimental neurology 141 (1), 32-39, 1996 | 319 | 1996 |
Dopamine induces apoptosis-like cell death in cultured chick sympathetic neurons—a possible novel pathogenetic mechanism in Parkinson's disease I Ziv, E Melamed, N Nardi, D Luria, A Achiron, D Offen, A Barzilai Neuroscience letters 170 (1), 136-140, 1994 | 311 | 1994 |
Stimulation of nigrostriatal dopamine neurones by nicotine W Lichtensteiger, F Hefti, D Felix, T Huwyler, E Melamed, M Schlumpf Neuropharmacology 21 (10), 963-968, 1982 | 292 | 1982 |